Grape King Bio Ltd (TPE:1707)
Taiwan · Delayed Price · Currency is TWD 121.00
-0.50 (-0.41%)
Feb 2, 2026, 1:35 PM CST
Grape King Bio Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 10,404 | 11,160 | 10,635 | 10,391 | 9,798 | 9,168 | |
Revenue Growth (YoY) | -7.15% | 4.93% | 2.35% | 6.05% | 6.87% | -0.77% |
Cost of Revenue | 2,532 | 2,502 | 2,099 | 1,909 | 1,942 | 1,631 |
Gross Profit | 7,872 | 8,658 | 8,536 | 8,482 | 7,856 | 7,537 |
Selling, General & Admin | 5,419 | 5,866 | 5,747 | 5,639 | 5,252 | 4,979 |
Research & Development | 292.54 | 291.91 | 289.55 | 289.88 | 292.23 | 252.86 |
Other Operating Expenses | -0.42 | 0.02 | 2.48 | 1.1 | 0.57 | -0.05 |
Operating Expenses | 5,711 | 6,158 | 6,039 | 5,930 | 5,544 | 5,232 |
Operating Income | 2,161 | 2,500 | 2,497 | 2,552 | 2,312 | 2,305 |
Interest Expense | -4.32 | -3.04 | -2.54 | -2.29 | -3.93 | -14.24 |
Interest & Investment Income | 45.66 | 49.97 | 47.6 | 19.92 | 6.29 | 4.63 |
Earnings From Equity Investments | 23.44 | 22.24 | 19.87 | 10.82 | 2.23 | 1.68 |
Currency Exchange Gain (Loss) | -8.99 | - | - | 11.63 | -2.24 | -6.17 |
Other Non Operating Income (Expenses) | 101.75 | 104.3 | 99.02 | 94.1 | 99.35 | 87.95 |
EBT Excluding Unusual Items | 2,318 | 2,673 | 2,661 | 2,686 | 2,413 | 2,379 |
Gain (Loss) on Sale of Investments | -0.43 | - | - | -1.91 | 0.8 | - |
Gain (Loss) on Sale of Assets | -0.75 | - | - | 3.76 | 0.82 | -0.46 |
Other Unusual Items | -1.18 | - | - | 0.11 | - | - |
Pretax Income | 2,316 | 2,673 | 2,661 | 2,688 | 2,415 | 2,378 |
Income Tax Expense | 440.37 | 502.15 | 519.11 | 518.19 | 466.92 | 483.1 |
Earnings From Continuing Operations | 1,876 | 2,171 | 2,142 | 2,170 | 1,948 | 1,895 |
Minority Interest in Earnings | -655.28 | -722.85 | -688.78 | -712.58 | -647.57 | -623.07 |
Net Income | 1,220 | 1,448 | 1,453 | 1,457 | 1,300 | 1,272 |
Net Income to Common | 1,220 | 1,448 | 1,453 | 1,457 | 1,300 | 1,272 |
Net Income Growth | -16.98% | -0.30% | -0.30% | 12.05% | 2.23% | -2.83% |
Shares Outstanding (Basic) | 148 | 148 | 148 | 148 | 148 | 136 |
Shares Outstanding (Diluted) | 149 | 149 | 149 | 149 | 148 | 137 |
Shares Change (YoY) | -0.08% | 0.00% | 0.06% | 0.45% | 8.41% | 0.21% |
EPS (Basic) | 8.24 | 9.78 | 9.81 | 9.84 | 8.81 | 9.34 |
EPS (Diluted) | 8.19 | 9.71 | 9.74 | 9.78 | 8.76 | 9.29 |
EPS Growth | -16.82% | -0.31% | -0.41% | 11.64% | -5.71% | -3.03% |
Free Cash Flow | 1,749 | 1,249 | 1,932 | 2,504 | 2,267 | 1,505 |
Free Cash Flow Per Share | 11.73 | 8.38 | 12.96 | 16.80 | 15.28 | 11.00 |
Dividend Per Share | 6.400 | 6.900 | 6.900 | 6.900 | 6.100 | 6.400 |
Dividend Growth | -33.33% | - | - | 13.11% | -4.69% | -1.54% |
Gross Margin | 75.66% | 77.58% | 80.26% | 81.63% | 80.18% | 82.20% |
Operating Margin | 20.77% | 22.40% | 23.47% | 24.56% | 23.59% | 25.14% |
Profit Margin | 11.73% | 12.98% | 13.66% | 14.02% | 13.27% | 13.87% |
Free Cash Flow Margin | 16.81% | 11.19% | 18.17% | 24.09% | 23.14% | 16.42% |
EBITDA | 2,696 | 3,013 | 2,956 | 2,936 | 2,679 | 2,658 |
EBITDA Margin | 25.91% | 27.00% | 27.80% | 28.26% | 27.34% | 28.99% |
D&A For EBITDA | 535.5 | 513.48 | 459.76 | 384.63 | 367.68 | 352.76 |
EBIT | 2,161 | 2,500 | 2,497 | 2,552 | 2,312 | 2,305 |
EBIT Margin | 20.77% | 22.40% | 23.47% | 24.56% | 23.59% | 25.14% |
Effective Tax Rate | 19.02% | 18.78% | 19.51% | 19.28% | 19.34% | 20.31% |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.